Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active RA in spite of stable dose of MTX~Exclusion Criteria:~* Having received infliximab in the past~* Having a history of serious infection which caused hospitalization within 6 months before the registration~* Having an active tuberculosis~* Having a complication or a history of malignancy within 5 years before the registration

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TA-650 3 mg/kg (Type: EXPERIMENTAL): None
- TA-650 6 mg/kg (Type: EXPERIMENTAL): None
- TA-650 10 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).